Estrogen replacement and weight gain: what the 2026 research says about where the fat goes

Estrogen replacement and weight gain: what the 2026 research says about where the fat goes

Weight climbs at a steady rate through the years before menopause, and the menopause transition does not make that climb any faster. What changes is what the weight is made of. Data from the Study of Women's Health Across the Nation found that at the start of the transition, the rate of fat gain doubled while lean mass declined, and that this happened independently of getting older.

That distinction matters more than the number on the scale. Fat that once sat on the hips and thighs starts collecting around the abdomen and inside the chest cavity, close to the heart and liver. This deeper fat behaves differently from the fat under your skin. It releases inflammatory signals directly into circulation and raises cardiovascular risk in a way that body mass index does not capture.

This article explains what happens to fat storage when estrogen falls, why a new 2026 paper draws a line between ordinary menopausal weight gain and the high-risk version of it, and what the evidence supports for managing the change.

In this article

Key takeaways

The shift The effect
Rate of fat gain doubles at the start of the menopause transition SWAN data show this is driven by the transition itself, not by chronological aging
Overall weight gain does not accelerate Fat rises and lean mass falls at the same time, so the scale hides the change in composition
Fat moves from hips and thighs to the abdomen and chest cavity Visceral fat sits near the liver and heart and releases inflammatory signals into circulation
The 2026 Menopause paper separates menopausal obesity from high-risk menopausal obesity The high-risk form carries clinical cardiovascular disease and shortened lifespan
Women on hormone therapy in the OsteoLaus cohort had lower visceral fat The 10-year gain in visceral fat was prevented in current users, with no residual benefit after stopping
BMI misses the change entirely Waist circumference tracks visceral fat far better than weight or BMI


What happens to fat storage when estrogen falls

Estrogen is not only a reproductive hormone. It acts on fat tissue directly, and it influences three separate things at once: how sensitive your brain is to the appetite signal leptin, how much energy your body burns at rest, and where fat gets deposited.

During the reproductive years, estrogen pushes fat storage toward the hips, thighs and buttocks. That pattern is metabolically quiet. Subcutaneous fat in those areas acts largely as a storage depot and produces relatively little inflammatory signalling. As estradiol falls, that directive weakens, and the body defaults to a storage pattern closer to the male one: fat around the middle, packed between the organs.

The 2019 SWAN analysis published in JCI Insight measured this with dual energy X-ray absorptiometry across repeated visits, timed against each woman's final menstrual period. Fat and lean mass both rose in the years before the transition. At the start of the transition, the rate of fat gain doubled and lean mass began to fall. Both trajectories continued until roughly two years after the final period, then flattened. Total weight, meanwhile, climbed in a straight line the whole way through with no acceleration at all.

That last detail explains why so many women feel gaslit by their own bathroom scale. The scale says nothing has changed. Clothes say otherwise. Both are correct, because fat is going up while muscle is going down, and the two roughly cancel out in kilograms.

The loss of lean mass compounds the problem. Muscle is metabolically active tissue. Less of it means fewer calories burned at rest, which makes the same diet that worked at 42 produce a different result at 50. Waist to hip ratio climbs through all of this even when body weight holds perfectly steady, which is the clearest sign that the storage pattern has shifted rather than the total amount.

The line the 2026 paper draws between menopausal obesity and high-risk menopausal obesity

In June 2026, the journal Menopause published a perspective piece by Maria Maturana, Fabiola Satler and Frederick Naftolin titled "Estrogen prevents menopausal obesity." Its central move is to split one condition into two.

The authors describe menopausal obesity, which they abbreviate MO, as the weight gain that follows the loss of ovarian estrogen. They then describe a second category: high cardiovascular risk menopausal obesity, or HRMO. This is the version in which visceral fat accumulation has progressed far enough to be associated with clinical cardiovascular disease and a shortened lifespan. Their argument is that estrogen, delivered as menopausal hormone therapy, has been shown to prevent or slow both the development of MO and the accumulation of intrathoracic visceral fat that drives the shift into HRMO.

Why intrathoracic fat gets its own mention. Fat inside the chest cavity sits directly around the heart. Pericardial and epicardial fat are not passive padding. They sit within the same blood supply as the heart muscle and secrete inflammatory cytokines locally. Abdominal visceral fat drains through the portal vein straight into the liver, which is why it affects liver fat, insulin sensitivity and lipid production so directly.

Why BMI does not see any of this. Two women at an identical BMI of 27 might carry entirely different visceral fat loads. One stores it under the skin. The other stores it around her organs. Their cardiovascular risk profiles are not comparable, and no weight-based number distinguishes them.

What the paper is and is not. This is a personal perspective built on observational data, animal models and existing mechanistic research. It is not a randomised controlled trial, and the authors do not present it as one. They state plainly that they are making a case for hormone therapy to be considered for this effect alongside its established uses. Read it as a well-argued position, not as settled proof.

How the loop reinforces itself. Falling estradiol removes the signal that directed fat toward subcutaneous storage, so new fat lands around the organs instead. Estrogen also influences leptin sensitivity, so the brain registers fullness less efficiently at the same moment the storage pattern changes. Declining lean mass lowers resting energy expenditure. Expanding visceral fat drives insulin resistance, and higher circulating insulin promotes further storage. Each step makes the next one easier, which is why this gets harder to interrupt the longer it runs.

Four other factors feed the same loop:

  • Disrupted sleep from night sweats, which raises next-day appetite and cortisol
  • Reduced physical activity as joint pain and fatigue increase
  • Chronic stress, which drives cortisol and preferentially adds abdominal fat
  • Alcohol intake, which the liver processes ahead of everything else

What the evidence supports for midlife fat redistribution

Resistance training and protein. The lean mass loss documented in SWAN is the single most modifiable part of this picture. Resistance training two or three times a week, paired with adequate protein, directly opposes the muscle decline. Most guidance for women over 50 sits around 1.0 to 1.2 grams of protein per kilogram of body weight daily, spread across meals rather than loaded into dinner.

Berberine. A 2020 systematic review and meta-analysis in Clinical Nutrition ESPEN pooled 12 randomised controlled trials and found berberine supplementation reduced body weight by an average of 2.07 kg, body mass index by 0.47, waist circumference by 1.08 cm, and C-reactive protein by 0.42 mg/L. The waist circumference and CRP findings are the interesting ones here, because they point at abdominal fat and inflammation rather than weight alone. Berberine works mainly by activating AMPK, an enzyme that improves how cells take up and use glucose.

Blood sugar stability. Insulin resistance and visceral fat reinforce each other. Anything that flattens post-meal glucose spikes interrupts that loop: fibre at the start of a meal, protein with carbohydrate rather than alone, and a short walk after eating.

Sleep. Short sleep raises ghrelin, lowers leptin and increases next-day intake. When night sweats are fragmenting sleep, treating the sleep disruption is a metabolic intervention, not only a comfort one.

Waist circumference tracking. Measure at the level of the navel, first thing in the morning, once a month. Above 88 cm, or 35 inches, is the commonly used threshold for elevated cardiometabolic risk in women. This number moves when the scale does not.

Pro Tip: Take berberine 15 to 30 minutes before your two largest meals rather than once daily. Its effect on glucose uptake is tied to the meal, and splitting the dose also reduces the digestive upset that puts some women off it in the first week.

Hormone therapy, metabolic support, and training: what each one does

The 2026 paper argues that hormone therapy deserves a place in this conversation. That does not make it the right choice for every woman, and it is not a decision to make from an article. What follows is a summary of what each approach addresses, so the conversation with your doctor starts from a clearer place.

Approach Pros Considerations Best for
Menopausal hormone therapy Addresses the underlying hormonal driver; OsteoLaus data associate current use with lower visceral fat Prescription only; eligibility depends on personal and family history; benefits were not preserved after stopping Women already considering hormone therapy for other menopause symptoms
Resistance training and protein Directly opposes the lean mass loss; no prescription needed; benefits bone density too Requires consistency over months; results show in body composition before they show on the scale Every woman in this stage, regardless of what else she does
Berberine and metabolic support Trial data show reductions in waist circumference and CRP alongside modest weight change Effects are moderate; interacts with some medications including metformin and statins Women whose main concern is abdominal fat and blood sugar stability
GLP-1 medications Substantial weight reduction in trials Prescription only; cost and access vary; lean mass loss is a documented concern without resistance training Women with obesity-related conditions under medical supervision
Calorie restriction alone Familiar and free Accelerates lean mass loss when protein and training are absent, which worsens the underlying problem Short-term use only, and only alongside protein and resistance work

 

These approaches are not mutually exclusive, and the strongest combination for most women is the least dramatic one: resistance training plus adequate protein, with metabolic support layered on top. Hormone therapy sits in a separate category because it requires a prescriber who knows your history.

One detail from the OsteoLaus cohort deserves attention. The researchers compared current users, past users and never users of hormone therapy across 1,053 women. Current users had lower visceral fat after adjusting for age, and the ten-year gain in visceral fat was prevented in that group. Past users showed no residual benefit at all, including those who stopped early. Whatever protection hormone therapy offers here appears to depend on continuing it.

Know when to seek professional evaluation:

  • Waist circumference above 88 cm, or 35 inches, particularly with a family history of heart disease or diabetes
  • Rapid weight gain of more than 5 kg over a few months without a change in diet or activity
  • Fasting glucose, HbA1c or triglycerides drifting upward on routine bloodwork
  • Blood pressure creeping up alongside the change in body shape
  • You are considering hormone therapy and want your personal risk profile assessed properly
  • You are taking metformin, a statin, a blood thinner or a blood pressure medication and want to add a supplement

Where Botavive Berberine 1200 fits in a metabolic plan

The gap most women run into is that the general advice for midlife weight is aimed at the scale, while the problem the research describes is about fat distribution and insulin sensitivity. Eating less does not address either one directly, and it works against you if it costs you muscle.

Botavive Berberine 1200 delivers berberine HCl at a 1200 mg equivalent daily dose. Berberine activates AMPK, the cellular pathway that governs how efficiently your cells take up and use glucose. In the pooled trial data, that translated into reductions in waist circumference and C-reactive protein alongside modest changes in weight, which maps onto the abdominal fat and inflammation pattern this article has been describing.

It is one part of a plan, not the plan itself. Resistance training and protein do the work on lean mass, and nothing in a capsule substitutes for that. If you take prescription medication for blood sugar, cholesterol or blood pressure, speak to your doctor before adding berberine, because it interacts with several of them.

Frequently asked questions

Does estrogen replacement cause weight gain or prevent it?

This is the most common misunderstanding about the topic. The concern that hormone therapy causes weight gain is widespread, but the observational data point the other way on fat distribution. In the OsteoLaus cohort, current hormone therapy users had lower visceral fat and lower BMI after adjusting for age than never users. The 2026 Menopause paper argues the same case from the mechanistic side.

If my weight has not changed, why do my clothes fit differently?

Because fat and lean mass are moving in opposite directions at similar rates. The SWAN analysis found total weight climbed in a straight line through the transition with no acceleration, while fat gain doubled and lean mass fell. Your scale is measuring the sum. Your waistband is measuring the composition.

Is visceral fat reversible, or is this permanent once it accumulates?

Visceral fat responds to intervention more readily than subcutaneous fat does. It is metabolically active, which means it is also metabolically responsive. Improvements in insulin sensitivity, resistance training and reduced inflammation all reduce it, and waist circumference typically moves before overall weight does.

How long does the accelerated fat gain phase last?

In the SWAN data, the accelerated fat gain and lean mass loss began at the start of the menopause transition and continued until roughly two years after the final menstrual period. After that, both trajectories flattened. That gives most women a window of several years where the change is most rapid and intervention matters most.

Should I be tracking anything other than weight?

Waist circumference is the single most useful home measurement, because it tracks visceral fat and BMI does not. On bloodwork, fasting glucose, HbA1c, triglycerides and HDL together give a reasonable picture of whether insulin resistance is developing. Ask for them at your next appointment if they are not already routine.

Sources

  1. Maturana MA, Satler F, Naftolin FN, 2026. Personal perspective in Menopause arguing that estrogen as menopausal hormone therapy prevents or retards menopausal obesity and the development of intrathoracic visceral fat. PubMed 42228467
  2. Greendale GA, Sternfeld B, Huang M, et al, 2019. SWAN cohort analysis in JCI Insight finding that the rate of fat gain doubled and lean mass declined at the start of the menopause transition, independently of chronological aging. PubMed 30843880
  3. Papadakis GE, Hans D, Gonzalez Rodriguez E, et al, 2018. OsteoLaus cohort study in the Journal of Clinical Endocrinology and Metabolism associating current menopausal hormone therapy use with lower visceral adipose tissue and prevention of the ten-year gain. PubMed 29596606
  4. Asbaghi O, Ghanbari N, Shekari M, et al, 2020. Meta-analysis of 12 randomised controlled trials in Clinical Nutrition ESPEN reporting reductions in body weight, BMI, waist circumference and C-reactive protein with berberine supplementation. PubMed 32690176

Related articles

Previous post Next post
Back to blog